Navigation Links
South Carolina Optometrists Partner with State Legislators and Local Mayors in Improving Infant Eye and Vision Care
Date:9/20/2010

CHARLESTON, S.C., Sept. 20 /PRNewswire/ -- Due to the overwhelming number of children with eye and vision problems across the United States, South Carolina optometrists are devoting appointments to no-cost, comprehensive eye and vision assessments for infants between six to 12 months of age through InfantSEE®.

InfantSEE®, a public health program developed by Optometry Cares - The AOA Foundation and Vistakon®, Johnson & Johnson Vision Care, Inc., was designed to provide professional eye care for infants nationwide at no-cost, regardless of family income or number of eligible children.  

"Detecting vision problems at an early age is the best way to ensure our children have healthy vision for successful development and learning," said Sen. Paul Campbell (R-44).  "Educating parents about the importance of establishing ongoing vision care for their children beginning at a very young age is also a top priority.  I encourage families in South Carolina to take advantage of this free eye examination through InfantSEE® and the South Carolina Optometric Physicians Association."

"What a wonderful gift of time and talent by South Carolina's optometrists to offer free eye exams to infants between birth and one year of age," said Sen. Luke Rankin (R-33).  "I encourage all South Carolinians to take advantage of this opportunity for early detection and treatment for our infant's vision problems."

Leading members of the South Carolina House have also expressed their support for the InfantSEE® program.

"This is a wonderful opportunity to have children at an early age get their vision tested," said Rep. Mike Sottile (R-112).  "This will only enhance the well being of the child for many years to come.  I just want to say thank you to the South Carolina optometrists for providing this great service."

"What a wonderful opportunity for all involved," said Rep. Joe Daning (R-92).  "
'/>"/>

SOURCE InfantSEE
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. Trana Discovery and Southern Research Institute Announce the First RNA-RNA High Throughput Drug Screening Assay Platform for HIV Antivirals
2. Artists for a New South Africa Will be Shaking The Blues at Gala Benefit November 15, With Performances by Erykah Badu, Nikka Costa, Keb Mo, Taj Mahal Trio, The Roots, and Guest Stars at The Wiltern in Los Angeles
3. Aeras, Crucell and South African Tuberculosis Vaccine Initiative Announce Encouraging Preliminary Results of Tuberculosis Vaccine Clinical Trial in South Africa
4. Quantum Immunologics, Inc. and the South Alabama Medical Science Foundation Announce an Early Clinical Evaluation of a Novel Immuno-therapeutic Vaccine for Treating Advanced Human Breast Carcinomas
5. BARC Announces Long-Term Cooperation In South African Biobanking for HIV Vaccine Trials
6. Anesiva Announces South Korea FDA Approval of Adlea(TM) Investigational New Drug Application
7. Positive Mosquito Count for West Nile Virus Lead DEP, Southeastern PA Counties to Ramp up Treatment Activities
8. DEP to Complete Aerial Mosquito Treatments to Stem West Nile Virus in Southeastern Counties
9. Cylex Announces Plan for Multi-Center Trial of ImmuKnow(R) Assay in South Korea
10. Southern Research Institute Wins $14.7 Million NIH Award to Participate in Molecular Libraries Probe Production Center Network
11. Clinical Trial Shows Cardiovascular Benefits of Rooibos, Popular Antioxidant Herbal Tea from South Africa
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/29/2014)... N.J. , July 29, 2014 Regado ... company focused on the Phase 3 clinical development of ... controllable antithrombotic drug system, today announced that it will ... Tuesday, Aug. 12, 2014, at 8:30 a.m. EDT to ... highlights. Interested participants and investors may access ...
(Date:7/29/2014)... 29, 2014  EnteroMedics Inc. (NASDAQ: ETRM ... to treat obesity, metabolic diseases and other gastrointestinal disorders, ... on Thursday, August 7, 2014 at 11:00 AM Eastern ... ended June 30, 2014 and to provide a business ... second quarter conference call may be accessed by dialing ...
(Date:7/29/2014)... (NYSE: CVD ) today reported results for ... was $639 million, representing 8.0% growth from the second ... reported earnings of $0.29 per diluted share in the ... diluted share of $0.95, up 21.5% over the second ... charges totaling $52.6 million, or $0.61 per share, and ...
Breaking Medicine Technology:Regado Biosciences to Provide Second Quarter 2014 Financial Results and Corporate Highlights 2Regado Biosciences to Provide Second Quarter 2014 Financial Results and Corporate Highlights 3EnteroMedics to Host Second Quarter 2014 Financial Results and Business Update Conference Call 2EnteroMedics to Host Second Quarter 2014 Financial Results and Business Update Conference Call 3Covance Reports Second Quarter Net Revenue Growth of 8.0% to $639 Million, Pro Forma EPS Growth of 21.5% to $0.95 and Adjusted Net Orders of $773 Million 2Covance Reports Second Quarter Net Revenue Growth of 8.0% to $639 Million, Pro Forma EPS Growth of 21.5% to $0.95 and Adjusted Net Orders of $773 Million 3Covance Reports Second Quarter Net Revenue Growth of 8.0% to $639 Million, Pro Forma EPS Growth of 21.5% to $0.95 and Adjusted Net Orders of $773 Million 4Covance Reports Second Quarter Net Revenue Growth of 8.0% to $639 Million, Pro Forma EPS Growth of 21.5% to $0.95 and Adjusted Net Orders of $773 Million 5Covance Reports Second Quarter Net Revenue Growth of 8.0% to $639 Million, Pro Forma EPS Growth of 21.5% to $0.95 and Adjusted Net Orders of $773 Million 6Covance Reports Second Quarter Net Revenue Growth of 8.0% to $639 Million, Pro Forma EPS Growth of 21.5% to $0.95 and Adjusted Net Orders of $773 Million 7Covance Reports Second Quarter Net Revenue Growth of 8.0% to $639 Million, Pro Forma EPS Growth of 21.5% to $0.95 and Adjusted Net Orders of $773 Million 8Covance Reports Second Quarter Net Revenue Growth of 8.0% to $639 Million, Pro Forma EPS Growth of 21.5% to $0.95 and Adjusted Net Orders of $773 Million 9Covance Reports Second Quarter Net Revenue Growth of 8.0% to $639 Million, Pro Forma EPS Growth of 21.5% to $0.95 and Adjusted Net Orders of $773 Million 10Covance Reports Second Quarter Net Revenue Growth of 8.0% to $639 Million, Pro Forma EPS Growth of 21.5% to $0.95 and Adjusted Net Orders of $773 Million 11Covance Reports Second Quarter Net Revenue Growth of 8.0% to $639 Million, Pro Forma EPS Growth of 21.5% to $0.95 and Adjusted Net Orders of $773 Million 12Covance Reports Second Quarter Net Revenue Growth of 8.0% to $639 Million, Pro Forma EPS Growth of 21.5% to $0.95 and Adjusted Net Orders of $773 Million 13Covance Reports Second Quarter Net Revenue Growth of 8.0% to $639 Million, Pro Forma EPS Growth of 21.5% to $0.95 and Adjusted Net Orders of $773 Million 14Covance Reports Second Quarter Net Revenue Growth of 8.0% to $639 Million, Pro Forma EPS Growth of 21.5% to $0.95 and Adjusted Net Orders of $773 Million 15Covance Reports Second Quarter Net Revenue Growth of 8.0% to $639 Million, Pro Forma EPS Growth of 21.5% to $0.95 and Adjusted Net Orders of $773 Million 16Covance Reports Second Quarter Net Revenue Growth of 8.0% to $639 Million, Pro Forma EPS Growth of 21.5% to $0.95 and Adjusted Net Orders of $773 Million 17Covance Reports Second Quarter Net Revenue Growth of 8.0% to $639 Million, Pro Forma EPS Growth of 21.5% to $0.95 and Adjusted Net Orders of $773 Million 18Covance Reports Second Quarter Net Revenue Growth of 8.0% to $639 Million, Pro Forma EPS Growth of 21.5% to $0.95 and Adjusted Net Orders of $773 Million 19Covance Reports Second Quarter Net Revenue Growth of 8.0% to $639 Million, Pro Forma EPS Growth of 21.5% to $0.95 and Adjusted Net Orders of $773 Million 20Covance Reports Second Quarter Net Revenue Growth of 8.0% to $639 Million, Pro Forma EPS Growth of 21.5% to $0.95 and Adjusted Net Orders of $773 Million 21Covance Reports Second Quarter Net Revenue Growth of 8.0% to $639 Million, Pro Forma EPS Growth of 21.5% to $0.95 and Adjusted Net Orders of $773 Million 22Covance Reports Second Quarter Net Revenue Growth of 8.0% to $639 Million, Pro Forma EPS Growth of 21.5% to $0.95 and Adjusted Net Orders of $773 Million 23Covance Reports Second Quarter Net Revenue Growth of 8.0% to $639 Million, Pro Forma EPS Growth of 21.5% to $0.95 and Adjusted Net Orders of $773 Million 24
(Date:7/29/2014)... TUESDAY, July 29, 2014 (HealthDay News) -- Chlorine helps ... swimmers more likely to develop eye infections, doctors say. ... eyes as well as blurry vision, said Dr. Sampson ... Center in New Jersey. It,s important to understand ... pools washes away the outer film layer of the ...
(Date:7/29/2014)... Using quality improvement measures in eight of the ... Study Group, researchers have found a way to reduce ... dye. , Currently, 7-15 percent of these patients who ... with kidney injury, which can result in death or ... permanent dialysis, says a study published in the July ...
(Date:7/29/2014)... Historically, Memorial Day kicks off a three ... throughout that time by picnics, barbecues and beach outings. ... the start of a period that will witness a ... 2012 nearly 1.000 people were killed in crashes involving ... Labor Day. , The summer's warmer weather, longer days ...
(Date:7/29/2014)... Pendleton, SC (PRWEB) July 29, 2014 During ... Arthur L. Bruce, DMD & Associates, has had a steady ... more about dentistry. These students have now gone on to ... own practices, proving that the shadowing program helps college students ... school, Dr. Bruce has given them the chance to see ...
(Date:7/29/2014)... July 29, 2014 A team of ... Doug Ethell, PhD, has developed a blood test for ... and the development of Alzheimer’s disease interventions, according to ... is a puzzle, and this study represents one of ... over the past couple of years,” Ethell said. , ...
Breaking Medicine News(10 mins):Health News:Protect Your Eyes When Hitting the Pool 2Health News:Reducing kidney injury using a quality improvement method 2Health News:Narconon New Life Retreat Launches New Alcohol Prevention Program 2Health News:Arthur Bruce Dental Helps College Students 2Health News:Professor Develops Blood Test for Alzheimer’s Disease Risk 2
... ... , ... October 6, 2009 -- KelseyCare Advantage , a Houston-based Medicare Advantage plan serving ... Galveston on the Mainland, recently reported its Healthcare Effectiveness Data and Information Set (HEDIS) ...
... other dangers, but behavioral effects remain unclear, , TUESDAY, ... study to suggest an association between the plastics chemical ... report that BPA may affect the behavior of little ... displayed more "externalizing" behaviors, such as aggression and hyperactivity, ...
... SHANGHAI, China, Oct. 6 /PRNewswire-Asia-FirstCall/ -- ... leading Chinese firm,specializing in the manufacture, research, development, marketing ... team will attend the 2009 ROTH China Conference held ... The date, time and location of China-Biotics, presentation at ...
... found in red grapes, has been shown to improve ... little has been known about how these beneficial changes ... for publication in Endocrinology , a journal of ... key role in mediating resveratrol,s anti-diabetic actions, potentially paving ...
... ... Leading health and technology experts gathered recently at ... Health Technology SummitSM to explore advanced medical technologies being used to ... featured presentations was "Artificial Heart--Past, Current and Future," by Alexander Medvedev, ...
... ... Web Designs) is building and giving away 250 Free websites to the first ... so they have angered rivals and received a number of malicious phone calls ... they withdraw their offer to build these 250 free websites for small, local ...
Cached Medicine News:Health News:Local Medicare Advantage Plan Scores High on Diabetic Care and Blood Pressure Control 2Health News: Plastics Chemical Tied to Aggression in Young Girls 2Health News: Plastics Chemical Tied to Aggression in Young Girls 3Health News:China-Biotics, Inc. to Attend 2009 ROTH China Conference 2Health News:Future diabetes treatment may use resveratrol to target the brain 2Health News:Terumo Heart, Inc.'s DuraHeart™ Left-Ventricular Assist System Featured at Future of Health Technology Summit 2Health News:Terumo Heart, Inc.'s DuraHeart™ Left-Ventricular Assist System Featured at Future of Health Technology Summit 3Health News:SEO Consultant Top Rank Web Designs Gives Away 250 Free Websites 2Health News:SEO Consultant Top Rank Web Designs Gives Away 250 Free Websites 3Health News:SEO Consultant Top Rank Web Designs Gives Away 250 Free Websites 4
The DePuy ACE 8.0mm Cannulated Cancellous Screw incorporates TiMAX to provide superior strength, fatigue resistance and a lower modulus of elasticity when compared to similar stainless steel devices....
Smith & Nephew offers a wide variety of cannulated screw products. Most screw sizes are available in both partially threaded and fully threaded versions. , ,All systems optimize implant strength with...
Biomet® Arthrodesis Nail indications include: , Failed external fixation , Aseptic failed total knee arthroplasty , Periarticular fractures where repair is not possible , Limb salvage in tumor...
... Retrograde Humeral Nail enables fixation of humeral ... that may be associated with antegrade nailing. ... and distal interlocking using a nail-mounted targeting ... interlocking with the patient in the prone ...
Medicine Products: